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Background: Dengue Virus (DENV) associated disease is a major public health
problem. Assessment of HLA class II restricted DENV-specific responses is relevant
for immunopathology and definition of correlates of protection. While previous studies
characterized responses restricted by the HLA-DRB1 locus, the responses associated
with other class II loci have not been characterized to date. Accordingly, we mapped
HLA-DP, DQ, and DRB3/4/5 restricted DENV-specific CD4T cell epitopes in PBMCs
derived from the DENV endemic region Sri Lanka.
Methods: We studied 12 DP, DQ, and DRB3/4/5 alleles that are commonly expressed
and provide worldwide coverage >82% for each of the loci analyzed and >99% when
combined. CD4+ T cells purified by negative selection were stimulated with pools of
HLA-predicted binders for 2 weeks with autologous APC. Epitope reactive T cells were
enumerated using IFNγ ELISPOT assay. This strategy was previously applied to identify
DRB1 restricted epitopes. In parallel, membrane expression levels of HLA-DR, DP, and
DQ proteins was assessed using flow cytometry.
Results: Epitopes were identified for all DP, DQ, and DRB3/4/5 allelic variants albeit
with magnitudes significantly lower than the ones previously observed for the DRB1
locus. This was in line with lower membrane expression of HLA-DP and DQ molecules
on the PBMCs tested, as compared to HLA-DR. Significant differences between loci
were observed in antigen immunodominance. Capsid responses were dominant for
DRB1/3/4/5 and DP alleles but negligible for the DQ alleles. NS3 responses were
dominant in the case of DRB1/3/4/5 and DQ but absent in the case of DP. NS1
responses were prominent in the case of the DP alleles, but negligible in the case of
DR and DQ. In terms of epitope specificity, repertoire was largely overlapping between
DRB1 and DRB3/4/5, while DP and DQ loci recognized largely distinct epitope sets.
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Conclusion: The HLA-DP, DQ, and DRB3/4/5 loci mediate DENV-CD4 specific
immune responses of lower magnitude as compared to HLA-DRB1, consistent with their
lower levels of expression. The responses are associated with distinct and characteristic
patterns of immunodominance, and variable epitope overlap across loci.
Keywords: DENV, CD4+T cells, HLA-DP, HLA-DQ, HLA-DRB3/4/5, adaptive immunity
INTRODUCTION
The burden of DENV disease has dramatically increased
worldwide in the past decades. Recent epidemiological data
estimate that almost 400 million DENV infections occurs per
year, of which 25% are symptomatic and associated with
clinical presentations of various severity (1). These numbers
clearly highlight the health threat that DENV represents
worldwide (2, 3).
DENV-specific immune responses have been extensively
studied in past years, highlighting key roles of both B and T cell
responses during infection. Whether T cells play a greater role
in disease protection or pathogenesis has been debated. Several
recent studies have shown that both CD4 and CD8T cells can
exert a protective effect in the context of DENV infections (4–10).
This is in contrast to an earlier hypothesis that suboptimal cross-
reactive memory T cells may impair viral control upon secondary
heterologous infections (11–13).
To enable comprehensive worldwide assessment of the
magnitude, antigen specificity, and epitope repertoire associated
with DENV-specific T cells, several studies have been carried
out in the general populations of endemic areas and following
vaccination. At the level of CD8T cell responses, responses
restricted by more than 30 different HLA–A and B allelic variants
have been defined (6, 14–18). Several studies defined HLA class
II-restricted responses both in the endemic areas of Sri Lanka and
Nicaragua, and following vaccination (7, 8, 15, 17, 19–23).
HLA class II molecules are heterodimers composed of an
alpha and beta chain. DRB1 is a highly polymorphic locus
which encodes a beta chain which pairs with an essentially
monomorphic alpha chain. The same alpha chain also pairs
with the beta chains produced by the DRB3/4/5 locus. Similarly,
additional alpha and beta chains are encoded by the DP and
DQ loci (24, 25). Thus, in a heterozygote individual, a total of
eight different HLA class II heterodimers can be expressed (two
DRB1/DRA, two DRB3/4/5/DRA, two DP, and two DQs).
Our previous study of class II restricted DENV epitopes
focused on responses associated with HLA DRB1 allelic variants
since DRB1 is the most commonly studied human class II
molecule, and DRB1 restricts the majority of defined epitopes
in the literature. However, this initial focus was by definition
incomplete, since it did not address the contribution of the
DRB3/4/5, DP, and DQ loci. A general bias toward DRB1-
restriction may be observed throughout the scientific literature.
For instance, querying the Immune Epitope Database (IEDB)
(https://www.iedb.org) that collects a list of experimental data on
B and T cell epitopes, reveals that 1,027, 0, 8, and 0 instances
of DENV epitopes restricted by HLA-DRB1, -DRB3/4/5, -DP,
and -DQ loci, respectively. Thus, data available regarding DENV-
epitopes restricted for DRB3/4/5, DP, and DQ loci are scarce and
this represents an important gap of knowledge. In this study, we
sought to characterize the contribution of DRB3/4/5, DP, and
DQ and loci in DENV-specific CD4T cell immune responses and
compare it to the previously defined DRB1 locus.
MATERIALS AND METHODS
Human Blood Samples
A total of 120 peripheral blood samples were obtained from
healthy adult blood donors from the National Blood Center,
Ministry of Health, Colombo, Sri Lanka in an anonymous fashion
as previously reported (14). Both sexes were represented and
donors ranged from 18 to 60 years of age. All protocols described
herein, were approved by the institutional review boards of both
LJI and Medical Faculty, University of Colombo (serving as NIH
approved IRB for Genetech). Blood collection and processing was
performed, as previously described (14). The blood samples were
obtained before DENV serology screening. Serology screening
(described in depth in the section below) identified 96 samples
collected and used for this study with broad neutralization
profile, suggesting that the donors had experienced one or
more DENV infections prior to blood donation. Donor serology
informations are shown in Supplementary Table S1.
Serology
Serum neutralization assays were performed in Vero cells in all
the donors of this study as previously reported (26). Briefly, Vero-
81 cells (2 × 104 cells/well, ATCC no. CCL-81) were seeded
on 96-well flat-bottom tissue culture-treated plates (Greiner
Sigma Aldrich), and incubated at 37◦C overnight. Equal volumes
of DENV viruses (DENV-1 West Pac 74, DENV-2 S-16803,
DENV-3 CH54389, and DENV-4 TVP-360) and eight 4-fold
serial dilutions of heat inactivated human sera were mixed and
incubated for 1 h at 37◦C and then transferred to 96 well-
plate with complete cell monolayer. Plates were incubated for
1 h at 37◦C with 5% CO2 for virus adsorption. After washing,
an overlay medium (1%carboxymethylcellulose) (200 µl/well)
was added in the wells and incubated for 48 h. Carboxymethyl
cellulose solution was discarded, plates were washed and cells
were fixed with 4% para formaldehyde. Plates were blocked
primary antibody was added (crude mAb 4G2 pan-DENV anti-
E protein and 2H2 PrM binding antibody in 1:300 dilutions)
followed by wash and incubation with goat anti mouse IgG
–HPR conjugated (1:1,000 in blocking buffer). After washing,
True blue substrate was added (True Blue HRP substrate,
VWR). The number of foci were visualized and quantified
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by automatic counting using a CTL ImmunoSpot (Cellular
Technology Limited). The log10 of the reciprocal serum dilution
was plotted against relative infection, calculated as [(# spots
sample–# spots non-infected control)/(# spots (virus + normal
human serum)–# spots non-infected control)], and fitted with a
sigmoidal dose-response curve using GraphPad Prism software
version 8.0 (La Jolla, CA). The titer of antibody (serum dilution)
that achieved a 50% reduction in infection (50% neutralization
titer, NT50), is expressed as the reciprocal of the serum dilution.
Maximum infection was calculated from monolayers infected
in the presence of normal human serum. Stringent QC rules,
including the absolute sum of squares <0.2 and the coefficient
of determination (R2) of the non-linear regression >0.9, were
required to ensure the reliability of results. Serology results are
shown in Supplementary Table S1.
HLA Typing and Phenotype
Frequency Calculations
HLA typing was performed by an ASHI-accredited laboratory
at Murdoch University (Western Australia) for Class I (HLA
A; B; C) and Class II (DRB1, DRB3/4/5, DQA1/DQB1, DPB1)
as previously described (15, 22, 23). Allele and phenotype
frequencies for individual DP/DQ alleles in Sri Lanka population
have been previously described (27). Worldwide phenotype
frequency were calculated as previously described and based on
data available at DbMHC and allelefrequencies.net (15, 28–32).
Population combined coverage for DP, DQ, and DRB345 loci was
calculated as follows:












MHC Class II Binding Predictions and
Peptide Selection
A set of DENV peptides predicted to bind various DRB3/4/5
(DRB3∗0202, DRB4∗0101, DRB5∗0101), DP (DPA1∗01/
DPB1∗0401, DPA1∗0103/DPB1∗0201, DPA1∗0201/DPB1∗0101,
DPA1∗0301/DPB1∗0402), and DQ (DQA1∗0301/DQB1∗0302,
DQA1∗0101/DQB1∗0501, DQA1∗0102/DQB1∗0602,
DQA1∗0501/DQB1∗0201, DQA1∗0501/DQB1∗0301) alleles
was chosen based on criteria further described in the results
section. Fifteen-mer peptides from all serotypes were predicted
for their binding affinity to the selected HLA class II molecules
as previously described (15, 33, 34). This resulted in the synthesis
of 432, 448, and 562 predicted binding peptides for HLA-
DRB3/4/5, DP, and DQ and loci, respectively, (Mimotopes,
Victoria, Australia) as shown in Supplementary Table S1. For
screening purposes, pools of peptides predicted to bind each
of the HLA class II allelic variants were used for stimulation
and deconvoluted to the single peptide level as previously
reported (8, 15).
In vitro Expansion of Denv-Specific T Cells
and IFNγ Elispot Assay
CD4+T cells stimulation was performed as previously described
(8, 15). Briefly, frozen Peripheral Blood Mononuclear Cell
(PBMCs) were thawed and CD4+ T cells were isolated
by magnetic bead negative selection and co-cultured with
autologous APC derived from the positive selection in a 2:1
ratio. Cells were stimulated with DENV-specific pools kept at
37◦C in 5% CO2, IL-2 (10 U/mL; eBioscience) was added at 4,
7, and 11 days after initial antigenic stimulation and harvested
on day 14. Harvested cells were counted and plated 5 × 104
CD4+ T cells in triplicates in the presence of the HLA-matched
peptide pools used for stimulation [1µg/ml] and the individual
peptide contained in the pool used for stimulation [10µg/ml].
When the number of cells were not sufficient to test all the
peptides contained in the pool used for stimulation a factorial
approach has been followed, alternatively, all the peptides were
directly deconvoluted after 14 days restimulation. On day 14,
no additional APC were added to the culture. After 20 h of
incubation at 37◦C, cells were incubated with biotinylated IFNγ
mAb (mAb 7-B6-1 Mabtech, Stockholm, Sweden) for 2 h and
developed as previously described (7, 14).
Flow Cytometry
PBMCs from 10 randomly selected Sri Lankan donors were
evaluated for Class II MHC expression by flow cytometry using
anti-DR, -DP, or -DQ antibodies (LB3.1, B7/21, and SPV-L3
clones, respectively). Briefly, thawed PBMCs were counted and
the cell suspension adjusted to 1× 106 cells/ml. Cell suspensions
were washed by centrifugation in ice-cold FACS Buffer (PBS,
10% FBS) followed by incubation with unconjugated primary
antibodies for 30min at 4◦C. After subsequent wash steps,
cells were incubated with FITC-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch, Inc. West Grove, PA) for 30min
at 4◦C. Additionally, control cells were incubated with isotype
antibody only. Data were acquired on a BD FACSCantoTM
II analyzer and Median Fluorescence Intensities (MFI) were
determined using FlowJo v10 (FlowJo, LLC).
Cluster Analysis
A List of epitopes positive in more than one donor and restricted
to different HLA class II loci (DP, DQ,DRB3/4/5, and DRB1
for reference) has been clustered using identity threshold of
70% and the recommended Cluster-break method implemented
in cluster tool 2.0 (35) available in IEDB (http://tools.iedb.org/
cluster2/). The resultant clusters and singlets overlap across the
different HLA class II loci were then graphically shown in a
Venn diagram format using Venny 2.1 (http://bioinfogp.cnb.csic.
es/tools/venny/index.html).
RESULTS
Selection of a Set of HLA, DP, DQ, and
DRB3/4/5 Alleles Enabling High Population
Phenotypic Coverage
To assess the contribution of DRB3/4/5, DP, and DQ loci
in restricting DENV-specific responses, we selected three to
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five of the most frequent alleles worldwide for each locus
(Figure 1, white bars). In the case of the DRB3/4/5, these
allelic variants were DRB3∗0202, DRB4∗0101, and DRB5∗0101.
These alleles are found at frequencies in the 25–52% range,
and combined afford coverage of 87% (Figure 1A, white
bars). In the case of DP, we selected DPB1∗0401, DPB1∗0201,
DPB1∗0101, and DPB1∗0402. While the alpha chain of DP
molecule is also variable, haplotype, and typing data is not
generally available, the alpha chain is not very polymorphic, and
the polymorphisms are generally conservative. These alleles are
found at frequencies in the 16–41.6% range, and combined afford
a coverage of 85% (Figure 1B, white bars). In the case of DQ
we selected DQA1∗0301/DQB1∗0302, DQA1∗0101/DQB1∗0501,
DQA1∗0102/DQB1∗0602, DQA1∗0501/DQB1∗0201, and
DQA1∗0501/DQB1∗0301. These alleles are found at frequencies
in the 11.3–35.1% range, and combined afford coverage of 81.6%
(Figure 1C, white bars). The phenotypic coverage provided when
the three loci are combined (assuming no linkage disequilibrium
as a first approximation) was projected at >99%.
In our studies, we utilized PBMC from the general population
of Colombo, Sri Lanka. Accordingly we compared worldwide
frequencies with the ones observed in the Sri Lankan population
(Figure 1, black bars) based on HLA typing studies we previously
reported (27). In general, the selected alleles afforded good
population coverage also in the Sri Lankan population in the
48.2–83.4% range across loci. The phenotypic coverage provided
when the three loci are combined was projected at >98%.
For each allele, we then selected five to seven PBMC
samples for an immunogenicity screen as described in the
following section.
Identification of DENV-Derived Putative
DRB3/4/5, DP, and DQ Restricted Epitopes
We synthesized and screened sets of epitopes candidates
restricted for each of the selected HLA alleles derived from
each of the main four DENV serotypes, based on their
predicted capacity to bind each HLA allelic variant, as previously
described (8, 15). The number of predicted epitopes for
each allele combinations studied in Sri Lanka are shown in
Supplementary Table S2. Each of the peptide sets was screened
in 5–7 HLA matched donors, serologically screened, and
confirmed to be exposed to one or more DENV serotype prior
to blood drawn (Supplementary Table S1). A complete list of
all epitopes identified in this study, including HLA restriction,
response frequency, and DENV protein composition has been
submitted to the IEDB (http://www.iedb.org/subid/1000789) and
is available for reference in Supplementary Table S3.
We identified 111, 123, and 106 epitopes restricted by HLA-
DRB3/4/5, -DP, and –DQ, respectively. From the 340 epitopes
identified, 250 were newly identified and not previously reported
in the IEDB. For each HLA class II allele belonging to DRB3/4/5,
DP, or DQ loci, Table 1 shows the breadth and the magnitude of
the responses normalized by the number of instances each allele-
specific peptide set combination has been tested. On average,
we identified a repertoire breadth of five epitopes per allele
tested, ranging from 0 to 34 epitopes recognized in a single
donor and with an average response per epitope of 891 SFC/106
PBMCs (Table 1). The percentage of epitopes as a function of
the DENV serotype is also shown; we considered conserved
epitopes when sequences shared more than 70% of homology
after cluster analysis (35). We found that the majority of the
epitopes recognized are conserved across the DENV serotype
when 70% homology cutoff was used with an average of 60%
of the epitope recognized being conserved ranging between 55
and 70% across the DRB3/4/5, DP, and DQ loci. Overall, a
similar DENV serotype recognition was observed across the loci
analyzed (Table 1).
In terms of magnitude of responses, we calculated the average
magnitude of response per donor (or multiple donors used to test
the complete set of predicted peptide per HLA allele) by summing
the total responses for each of the various HLA class II alleles
studied and dividing the sum by the number of tested donors,
using the same methodology as previously reported for DRB1
alleles (15). As we sought to compare the DP, DQ, DRB3/4/5
data with the ones previously published on DRB1 (8, 15), we kept
consistent both experimental and analysis strategies.
Figure 2A shows the average magnitude of responses, where
each allele represent a data point. Despite a rather substantial
range of responses the median magnitude for responses
associated with the DRB3/4/5, DP, and DQ loci were similar, with
values of ∼4,000 SFC/donor. In particular, the range was highest
for DRB3/4/5, with the DRB3∗02:02 allele having the highest and
DRB4∗01:01 the lowest reactivity. These results represent the first
description of DENV-derived putative DRB3/4/5, DP, and DQ
restricted epitopes.
Comparison of Magnitude of HLA
DRB3/4/5, DP, and DQ vs. HLA
DRB1 Responses
Next we compared the responses in the case of the DRB3/4/5,
DP, and DQ loci with responses previously defined for different
DRB1 alleles (15), using the exact same methodology. For
each allele, the sum of magnitude of responses was added
and divided by the number of donors tested to calculate the
average magnitude/donor response. Figure 2A shows the average
magnitude of responses, for the DRB3/4/5, DP, and DQ loci,
compared to data from 16 DRB1 alleles previously published
(15) which is shown here for reference purposes. HLA-DRB1
was associated with higher magnitude of responses (about 2-
fold) compared to the other HLA class II loci combined (Mann
Whitney, p= 0.0473; Figure 2A).
We hypothesized that this increased magnitude of responses
could be due to a difference in cells surface expression of the
three different HLA class II loci. Indeed, several reports indicate
that DRB1 gene products are expressed at levels 5–10 higher
than those encoded by the DRB3/4/5, DP, and DQ loci (36). To
verify that this was also the case in our experimental system,
PBMCs derived from 10 randomly selected Sri Lanka blood
bank donors, were stained for the expression of HLA-DRA (the
antibody used could not therefore, discriminate between DRB1
and DRB3/4/5 loci) (37), DP, and DQ (38). As expected, we did
observe significantly higher (about 5-fold) expression of DR in
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FIGURE 1 | HLA class II phenotype frequencies in DP, DQ, and DRB3/4/5 loci. The HLA-DRB3/4/5 (A), -DP (B), and -DQ (C) phenotypic frequency and allele
coverage worldwide (white bars), is compared to the one observed in Sri Lanka donors (n = 714, black bars) and based on previously published data (27).
comparison with DP and DQ (Wilcoxon test, DP vs. DR p =
0.020; DQ vs. DR p = 0.002) (Figures 2B,C). Overall, the HLA-
DRB1 locus is associated with higher magnitude of responses,
which correlates with higher expression level on cell surfaces
among the various HLA class II loci.
Differences and Similarities in
Immunodominance Patterns of
DENV-Specific CD4+T Cells Responses
Protein as a Function of HLA-Class II Loci
We next analyzed the pattern of immunodominance of responses
as a function of the different HLA class II loci. Specifically, for
each HLA allelic variant we calculated the fraction of the total
response directed against each of the 10 antigens encoded by the
DENV polyprotein. We next investigated whether locus-specific
differences were present (Figure 3). For the sake of comparison,
we also included previously reported data, related to 16 alleles
of the DRB1 locus which showed a preferential response toward
capsid, NS3 and NS5 proteins (Figure 3). We emphasize that the
DRB1 data was previously published (15) and is shown here only
for reference purposes. This analysis revealed difference in the
pattern of immunodominance for some of the DENV antigens
(Figure 3). Pie charts showing the fraction of the total response
corresponding to each DENV protein are also shown to highlight
these differences (Supplementary Figure S1). Specifically, while
Capsid was dominantly recognized by DRB1 and DRB3/4/5
(accounting for about 25% of the response), it was only
marginally recognized by DQ alleles (p = 0.0442 in a Kruskal-
Wallis test). The NS1 antigen was dominantly recognized by
DP alleles, but only marginally by DRB1, DRB3/4/5, and DQ
loci (p = 0.0028 in a Kruskal-Wallis test). When looking at
the NS1- specific immunodominance observed in the context of
DP locus, we also identified an immunodominant NS1 region
(NS1933−949 DYGFGVFTTNIWLKLRE) recognized across the
four DP alleles (Supplementary Table S3). Conversely the NS3
antigen was not recognized by DP responses, but otherwise
dominantly recognized by DRB1, DRB3/4/5, and DQ loci (p =
0.0279 in a Kruskal-Wallis test).
DENV HLA Class II-Restricted Epitopes
Overlap Across the Different Loci
As a final analysis of similarity and differences in the CD4
responses to DENV as a function of different HLA loci, we
examined the responses for overlap at the level of the epitope
repertoires associated with each locus. For this purpose, we
considered epitopes that were positive in at least two of the
donors tested for each allele, also including those previously
identified in the context of DRB1 locus. As such we considered
22, 32, and 39 epitopes restricted to DP, DQ, and DRB3/4/5
restriction, respectively, for a total of 93 epitopes, and 183
epitopes restricted to DRB1 and previously identified in the same
population (15). To account for minor sequence variations and
difference in the peptide frame, these epitopes were clustered
using the cluster break-method at 70% of homology using cluster
2.0 tool available in IEDB (35). The results of this analysis
identified 112 epitope clusters shown as a Venn diagram in
Figure 4. Of those 112 clusters, 78 were recognized by DRB1
(70%). Of those 78, 11 were shared with DRB3/4/5 (14%), 6 with
DP (8%), while only 4 were shared with DQ (5%). In the case
of DRB3/4/5, 11 clusters were recognized (10%); all were shared
with DRB1 (100%), while only two with DP (18%), and two with
DQ (18%). In the case of DP, 11 clusters were recognized (10%);
of those six were shared with DRB1 (54%), while only two with
DRB3/4/5 (18%), and three with DQ (27%). Finally, in the case
of DQ, 24 clusters were recognized (21%); of those four were
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TABLE 1 | Characteristics of DENV-specific responses in DRB3/4/5, DP, and DQ loci.





















DRB3/4/5 DRB3*0202 6 2 162 271 10 10 10 0 70
DRB4*0101 6 5 591 2,661 11 11 4 0 74
DRB5*0101 7 11 1,921 20,309 3 11 8 12 66
DP DPB1*0101 6 4 622 2,694 8 4 8 8 73
DPB1*0201 6 3 308 873 6 6 18 6 65
DPB1*0401 5 8 892 7,166 10 0 20 10 61
DPB1*0402 5 8 1,165 9,087 23 10 18 8 41
DQ DQA1*0101/
DQB1*0501
5 6 1,514 9,525 12 18 3 9 59
DQA1*0102/
DQB1*0602
7 5 1,093 5,911 13 20 5 13 50
DQA1*0301/
DQB1*0302
6 3 1,375 4,082 11 21 0 26 42
DQA1*0501/
DQB1*0201
6 1 364 395 14 29 0 0 57
DQA1*0501/
DQB1*0301
6 1 680 635 17 0 0 17 67
Avg 6 5 891 5,301 11 12 8 9 60
*Factorial approach has been used for this study. Responses have been normalized based on the number of instances a full HLA allele-specific peptide set has been tested.
#Data calculated as (SFC/106 CD4).
FIGURE 2 | HLA class II loci comparison. (A) Magnitude of CD4+T cell responses per HLA class II allele expressed as SFC/106 CD4 cells/donor after in vitro
stimulation. (B) Membrane expression of HLA-DR, DP, DQ molecules in PBMCs expressed as Median Fluorescence Intensity (MFI). All statistical analysis were
performed using unpaired non-parametric Mann-Whitney test. *p < 0.05, **p < 0.01, ns, not significant. (C) Representative overlay histograms derived from one
donor PBMCs staining showing the membrane expression of isotype control (gray) overlayed with HLA-DR (black), DP (blue) or DQ (red) molecules, respectively.
shared with DRB1 (17%), two with DRB3/4/5 (8%), and three
with DP (12%).
Overall, these results suggest that there is large
overlap between DRB1 and DRB3/4/5 loci, with
DP showing an intermediate pattern of repertoire
overlap, and DQ being associated with a mostly
unique repertoire.
DISCUSSION
Dengue Virus-specific CD4+T cells responses are important in
the control of infection and strong responses were previously
associated with control of DENV infection in asymptomatic
individuals (39). We previously studied in the context of
DENV-specific CD4+T cell responses the role of DRB1 locus in
Frontiers in Immunology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 1568
Grifoni et al. HLA-DP, DQ in DENV-CD4+ T Cell
FIGURE 3 | Immunodominance protein pattern of HLA class II loci comparison. Protein immunodominance observed in the previously published HLA-DRB1 locus as
reference (black) (15) is compared with HLA-DP (red), HLA-DQ (blue), and HLA-DRB3/4/5 loci (green). Each dot represents the percentage of magnitude of responses
per allele in the respective locus divided for DENV protein composition. Statistical analysis per protein have been performed using one-way ANOVA non-parametric
Kruskal-Wallis test.
FIGURE 4 | DENV epitope overlap across HLA class II loci. The number of
epitopes positive in more than one donor have been clustered using cluster
2.0 (35) (http://tools.iedb.org/cluster2/) and shown as Venn diagram using
Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
different DENV endemic populations (8, 15). In this study, we
extended our analysis to DP, DQ, and DRB3/4/5 loci using the
same strategy and same DENV population previously reported
for DRB1 locus.
In general, in humans most defined restrictions are associated
with the DRB1 locus. By querying the IEDB (www.IEDB.org)
for T cell responses in human hosts that have known MHC
class II restriction, we found that 4,010 instances of epitopes
restricted by DRB1 molecules, in contrast to 348, 246, and
584 instances of DRB3/4/5, DP, and DQ restrictions. It is
however not clear based on this analysis alone, whether this data
preponderance is to be ascribed to the fact that these responses
are simply less frequently studied, or whether this reflect a
lower magnitude of responses/epitope numbers associated with
these loci.
Significantly weaker responses and lower number epitopes
were identified for DP, DQ, and DRB3/4/5 loci combined when
compared to DRB1 locus. These data are also consistent with
other studies which reported lower number of epitopes found
in DQ and DP loci compared to DR locus in both allergy,
autoimmune diseases and viral contexts (40–42). In the allergy
context, we have previously shown that the frequency of locus
distribution for HLA class II antigen-specific responses was the
highest for DR (61 and 49% of total SFC), followed by DP
(21 and 35% of total SFC), and DQ (18 and 16% of total
SFC) (42).
Given the 2 log variability in the magnitude of the CD4
response depending on the MHC II allele considered, it is
not obvious that DRB3/4/5 alleles induce responses of lower
magnitude compared to DRB1. However, when DRB3/4/5, DP,
and DQ loci are combined together we do observe a significant
lower magnitude of response respect to DRB1 locus. This is
consistent with the previously reported lower expression of
heterodimers encoded by DP, DQ, and DRB3/4/5 (43, 44), also
confirmed in our study. Specifically, we showed that HLA-DR
protein (which combines expression of bothDRB1 andDRB3/4/5
loci) is significantly more highly expressed on cell surface when
compared to DP and DQ loci, suggesting a higher probability
that epitopes DR-restricted are recognized by CD4+T cells
respect to DP and DQ. This evidence is consistent with other
studies showing the same pattern of protein expression in several
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Antigen Presenting Cells (APC) derived from PBMCs or cell
lines (43, 44).
As this study evaluated only IFNγ-specific T cell responses,
it cannot be excluded that epitope recognition in the context of
DP, DQ, and DRB3/4/5 could induce effector T cell responses
differing from IFNγ release. However, lower general reactivity of
DP and DQ compared with DR was noted as well by Kwok group
using tetramer reagents (personal communication), thus arguing
against this possibility.
Our results also show some qualitative differences between
the immunodominance of the responses restricted by the various
loci. Capsid was dominantly restricted by DR but marginally by
DP and DQ. NS1 is preferentially presented by DP, and NS3
responses are restricted by all loci except DP. These differences
are at least in part accounted by how frequent the peptides
carrying specific motifs are found in the various proteins. Further
studies should be focused on explaining why NS1 is more
efficiently recognized when restricted by DP compared with
other loci. In any case, these data reemphasize the fact that
MHC class II allele polymorphism is a key determinant of
immune responsiveness. Indeed, for this exact reason MHC class
II genes were originally labeled in the 1970s as “IR” or “Immune
Response” genes (45).
Finally, we considered the epitope repertoire overlap across
loci. When comparing the DRB1-restricted epitopes with the
ones identified in this study, a strong overlap is shown with
DRB3/4/5 loci. In contrast, less overlap was found between DR
and DP, and the least minimal overlap of DQ with the other
loci. The complete overlap of DRB3/4/5 locus with DRB1 is
consistent with the shared used of the alpha chain encoded by
the DRA gene. Previous data have shown similarity in binding
repertoire between DP and DRB1 loci based on similarities in
the peptide-binding motifs (30, 46). In contrast, DQ molecules
are associated with more loose peptide-binding motifs and
its peptide-binding capability appears more dependent on the
main backbone than the specific anchor position giving more
importance to the alpha and beta chain combination being
both polymorphic and both important in the characterization
of the peptide-binding capability (31). Overall the pattern of
epitope repertoire overlap is consistent with previous studies by
Greenbaum (47) utilizing large collections of peptide binding
assays and a collection of purified HLA molecules from different
alleles of the DP, DQ, DRB3/4/5, and DRB1 loci. Based on the
available knowledge, predictions for the HLA class II molecules
in each loci will cover ∼50% of the total response, with DRB1-
restrictred responses found to be dominant and an appreciable
fraction of the responses found instead to be restricted by DP,
DQ, andDRB3/4/5 loci (30, 31, 48–50). Our current dataset could
not alone evaluate the efficiency of epitope prediction but will
provide additional experimental data for future benchmarking
of DRB3/4/5, DP, and DQ epitope prediction. Additionally,
the present study by defining epitopes restricted by this loci
enables future studies to address the relevance of this loci
in DENV.
In conclusion, our data highlights that DP, DQ, and
DRB3/4/5 restricted are a minor but significant component
(as compared to DRB1 restrictions) in DENV-CD4 specific
T cell response. This is consistent with lower expression of
DP and DQ in APCs, and what has been reported in the
general literature for other immunogenic systems highlighting
the major role of HLA-DR in triggering CD4+ DENV-specific
T cell responses.
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